Siemens Fonds Invest GmbH Decreases Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Posted by on Jun 13th, 2023

Siemens Fonds Invest GmbH cut its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Get Rating) by 18.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,789 shares of the medical equipment provider’s stock after selling 407 shares during the period. Siemens Fonds Invest GmbH’s holdings in Zimmer Biomet were worth $228,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of ZBH. Fairfield Bush & CO. purchased a new position in shares of Zimmer Biomet in the 1st quarter valued at about $111,000. United Bank boosted its holdings in shares of Zimmer Biomet by 4.1% in the 1st quarter. United Bank now owns 11,072 shares of the medical equipment provider’s stock valued at $1,416,000 after buying an additional 437 shares in the last quarter. Panagora Asset Management Inc. boosted its holdings in shares of Zimmer Biomet by 153.9% in the 1st quarter. Panagora Asset Management Inc. now owns 9,803 shares of the medical equipment provider’s stock valued at $1,254,000 after buying an additional 5,942 shares in the last quarter. Aviva PLC lifted its holdings in shares of Zimmer Biomet by 0.4% in the 1st quarter. Aviva PLC now owns 30,636 shares of the medical equipment provider’s stock valued at $3,918,000 after purchasing an additional 137 shares during the last quarter. Finally, Allianz Asset Management GmbH lifted its holdings in shares of Zimmer Biomet by 11.2% in the 1st quarter. Allianz Asset Management GmbH now owns 41,816 shares of the medical equipment provider’s stock valued at $5,348,000 after purchasing an additional 4,224 shares during the last quarter. 87.21% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Price Performance

Shares of NYSE:ZBH opened at $135.55 on Tuesday. The business’s fifty day moving average price is $133.83 and its two-hundred day moving average price is $128.33. The stock has a market cap of $28.27 billion, a PE ratio of 63.34, a price-to-earnings-growth ratio of 2.48 and a beta of 1.01. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.93 and a current ratio of 1.89. Zimmer Biomet Holdings, Inc. has a one year low of $100.39 and a one year high of $149.25.

Zimmer Biomet (NYSE:ZBH – Get Rating) last released its earnings results on Tuesday, May 2nd. The medical equipment provider reported $1.89 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.64 by $0.25. The company had revenue of $1.83 billion for the quarter, compared to analyst estimates of $1.70 billion. Zimmer Biomet had a net margin of 6.33% and a return on equity of 12.43%. The firm’s quarterly revenue was up 10.1% on a year-over-year basis. During the same period in the prior year, the firm earned $1.61 EPS. On average, analysts forecast that Zimmer Biomet Holdings, Inc. will post 7.45 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, July 31st. Stockholders of record on Monday, June 26th will be given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.71%. The ex-dividend date is Friday, June 23rd. Zimmer Biomet’s dividend payout ratio is currently 44.86%.

Insider Activity at Zimmer Biomet

In other Zimmer Biomet news, VP Chad F. Phipps sold 23,045 shares of Zimmer Biomet stock in a transaction dated Friday, March 17th. The stock was sold at an average price of $124.50, for a total value of $2,869,102.50. Following the completion of the sale, the vice president now owns 43,671 shares in the company, valued at approximately $5,437,039.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.95% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. TheStreet raised shares of Zimmer Biomet from a “c” rating to a “b” rating in a report on Tuesday, May 2nd. Raymond James raised their price target on Zimmer Biomet from $144.00 to $160.00 in a report on Wednesday, May 3rd. SpectralCast reissued a “maintains” rating on shares of Zimmer Biomet in a report on Wednesday, May 3rd. Stifel Nicolaus raised their price target on Zimmer Biomet from $160.00 to $165.00 in a report on Thursday, May 18th. Finally, Bank of America raised Zimmer Biomet from an “underperform” rating to a “neutral” rating in a report on Wednesday, May 3rd. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $143.67.

Zimmer Biomet Company Profile

(Get Rating)

Zimmer Biomet Holdings, Inc engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products.

Featured Articles

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Get Rating).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.